This is an archive of past discussions. Do not edit the contents of this page. If you wish to start a new discussion or revive an old one, please do so on the current talk page. |
Archive 1 | Archive 2 |
This
edit request to
Heather Bresch has been answered. Set the |answered= or |ans= parameter to no to reactivate your request. |
Bresch has also advocated for broader availability of EpiPens in public places to treat anaphylaxis (severe allergic reactions),[17]
This is inaccurate as Heather Bresch has actually made it more difficult for families to have access to EpiPens by hiking the price over 600%
Here are a few sources: http://www.nydailynews.com/news/national/mylan-ceo-600-pay-increase-epipen-price-raise-article-1.2762769 http://www.nbcnews.com/business/consumer/mylan-execs-gave-themselves-raises-they-hiked-epipen-prices-n636591 http://www.latimes.com/business/hiltzik/la-fi-hiltzik-mylan-inversion-20160823-snap-story.html 96.84.133.145 ( talk) 13:49, 24 August 2016 (UTC)
Should have her birth date June 27, 1969. 50.79.227.209 ( talk) 18:36, 25 August 2016 (UTC)
This
edit request to
Heather Bresch has been answered. Set the |answered= or |ans= parameter to no to reactivate your request. |
I am listed as an author used to contribute to the article on Heather Bresch, but my name is wrong. It should be Burnside, Mary Wade, not Burnside, Mary.
YogaCat ( talk) 11:23, 26 August 2016 (UTC)
That's fine. I'm not the person who added the content or reference in the first place. I would have gotten my name correct. Thank you. YogaCat ( talk) 13:05, 26 August 2016 (UTC)
I'm thinking that this is no longer a "good" article. All the negative stuff about Epipens applies pretty directly to the company, but I don't see any connection to Heather Bresch. Also there is a sentence fragment about Epipens in the introduction. Lou Sander ( talk) 04:16, 23 August 2016 (UTC)
The following content was added here. I removed it here. The original editor restored it here. I removed it again here, and have opened this discussion.
Bresch defended the EpiPen price hike, telling the 'New York Times: "I think we mean what we say: You can do good and do well, and I think we strike that balance around the globe ... I am running a business. I am a for-profit business. I am not hiding from that." [1] Bresch pointed out that the list price of EpiPens does not accurately reflect Mylar's sales price since intermediaries (wholesalers, retailers, pharmacy benefit managers, etc.) add to the final cost. [2] She added that the price hikes serve to subsidize the lower costs of EpiPens outside of the United States. [2]
References
In my view the content provided by the editor, "Bresch defended the EpiPen price hike" doesn't accurately reflect the source and is OR. The NYT never says that she defended the price hike.
What the NYT actually says is "Still, she was unapologetic that Mylan’s actions were driven by profit. “I am running a business. I am a for-profit business. I am not hiding from that.”"
The article does present three things she had to say (two of which which are not actually defenses) she offered: 1) "the company’s latest actions would do the most to help patients where it mattered, by reducing their out-of-pocket costs." 2) "And she said that the $600 list price was necessary for the company to recoup its investment in the EpiPen, which includes raising awareness for severe allergic reaction and making improvements to the way the product works." (this is the actual defense): 3) "But she also sought to shift blame away from Mylan, saying that patients are feeling the pain in part because insurers have increased the amount that customers must pay in recent years."
I am not opposed to including some content about what Bresch had to say but it needs to be accurate and what Mylan has to say needs to be contextualized. Let's work something out. Jytdog ( talk) 19:08, 27 August 2016 (UTC)
User:Rms125a@hotmail.com please stop breaking up the paragraph on the epipen as you did here and then edit warred back in here.
As I noted in my edit note here: this is all one idea in the article; the lead sentence of the paragraph serves the purpose of saying what is coming. There is a lot of other stuff going on in this section and breaking the epipen stuff into multiple paragraphs mushes it with the rest of the content there. Jytdog ( talk) 02:13, 29 August 2016 (UTC)
When we use a term such as "unearned" in Wikipedia's voice, we are making a leap here. Proper policy is to cite sources, not to editorially assert this as simple fact. And using parenthetical comments about any such case is against common sense. Collect ( talk) 13:26, 29 August 2016 (UTC)
There have been two edits recently adding and then reverting the "Known for" line of the infobox with "Raising the prices of EpiPens by 400%". Realizing we must be mindful of WP:BLP, this appears accurate to include, to me. In a quick google news search, both recent [1] [2] and older [3] references refer to this event. Even references to Heather Bresch in articles not primarily about her refer to this fact. [4] [5] [6] [7] I don't think there is a "standard" for being Known for, but I believe there is sufficient reliable sources for it's use here. Hopefully we can find a consensus here.
(This isn't a particularly active article, notifying editors who have worked on the article recently: Edwardx, Shearonink, Nomoskedasticity, Michael Powerhouse, Koavf, Bitmapped, Joeykai) Dbsseven ( talk) 22:20, 5 June 2018 (UTC)
She has three controversial/noteworthy things that she is "known for". Instead of trying to cover them in an infobox, IMHO it would be better to have a Controversy section or similar. Lou Sander ( talk) 22:38, 27 June 2018 (UTC)
Hi. Either Heather Bresch started working for Mylan in 1991 or in 1992 - both stories cannot be correct, as written... This needs to be definitively cleaned up. — Preceding unsigned comment added by Stevenmitchell ( talk • contribs) 05:10, 19 July 2021 (UTC)
Discrepancy. Her resume in the right-hand column of the article states that she received a BA from Harvard Law, whereas the text of the article states that she received a BA from WV University. And, isn’t a law degree is a JD? 72.227.105.116 ( talk) 02:45, 20 December 2021 (UTC)
Summary and personal life sections are in disagreement. 152.44.208.181 ( talk) 21:05, 30 May 2023 (UTC)
This is an archive of past discussions. Do not edit the contents of this page. If you wish to start a new discussion or revive an old one, please do so on the current talk page. |
Archive 1 | Archive 2 |
This
edit request to
Heather Bresch has been answered. Set the |answered= or |ans= parameter to no to reactivate your request. |
Bresch has also advocated for broader availability of EpiPens in public places to treat anaphylaxis (severe allergic reactions),[17]
This is inaccurate as Heather Bresch has actually made it more difficult for families to have access to EpiPens by hiking the price over 600%
Here are a few sources: http://www.nydailynews.com/news/national/mylan-ceo-600-pay-increase-epipen-price-raise-article-1.2762769 http://www.nbcnews.com/business/consumer/mylan-execs-gave-themselves-raises-they-hiked-epipen-prices-n636591 http://www.latimes.com/business/hiltzik/la-fi-hiltzik-mylan-inversion-20160823-snap-story.html 96.84.133.145 ( talk) 13:49, 24 August 2016 (UTC)
Should have her birth date June 27, 1969. 50.79.227.209 ( talk) 18:36, 25 August 2016 (UTC)
This
edit request to
Heather Bresch has been answered. Set the |answered= or |ans= parameter to no to reactivate your request. |
I am listed as an author used to contribute to the article on Heather Bresch, but my name is wrong. It should be Burnside, Mary Wade, not Burnside, Mary.
YogaCat ( talk) 11:23, 26 August 2016 (UTC)
That's fine. I'm not the person who added the content or reference in the first place. I would have gotten my name correct. Thank you. YogaCat ( talk) 13:05, 26 August 2016 (UTC)
I'm thinking that this is no longer a "good" article. All the negative stuff about Epipens applies pretty directly to the company, but I don't see any connection to Heather Bresch. Also there is a sentence fragment about Epipens in the introduction. Lou Sander ( talk) 04:16, 23 August 2016 (UTC)
The following content was added here. I removed it here. The original editor restored it here. I removed it again here, and have opened this discussion.
Bresch defended the EpiPen price hike, telling the 'New York Times: "I think we mean what we say: You can do good and do well, and I think we strike that balance around the globe ... I am running a business. I am a for-profit business. I am not hiding from that." [1] Bresch pointed out that the list price of EpiPens does not accurately reflect Mylar's sales price since intermediaries (wholesalers, retailers, pharmacy benefit managers, etc.) add to the final cost. [2] She added that the price hikes serve to subsidize the lower costs of EpiPens outside of the United States. [2]
References
In my view the content provided by the editor, "Bresch defended the EpiPen price hike" doesn't accurately reflect the source and is OR. The NYT never says that she defended the price hike.
What the NYT actually says is "Still, she was unapologetic that Mylan’s actions were driven by profit. “I am running a business. I am a for-profit business. I am not hiding from that.”"
The article does present three things she had to say (two of which which are not actually defenses) she offered: 1) "the company’s latest actions would do the most to help patients where it mattered, by reducing their out-of-pocket costs." 2) "And she said that the $600 list price was necessary for the company to recoup its investment in the EpiPen, which includes raising awareness for severe allergic reaction and making improvements to the way the product works." (this is the actual defense): 3) "But she also sought to shift blame away from Mylan, saying that patients are feeling the pain in part because insurers have increased the amount that customers must pay in recent years."
I am not opposed to including some content about what Bresch had to say but it needs to be accurate and what Mylan has to say needs to be contextualized. Let's work something out. Jytdog ( talk) 19:08, 27 August 2016 (UTC)
User:Rms125a@hotmail.com please stop breaking up the paragraph on the epipen as you did here and then edit warred back in here.
As I noted in my edit note here: this is all one idea in the article; the lead sentence of the paragraph serves the purpose of saying what is coming. There is a lot of other stuff going on in this section and breaking the epipen stuff into multiple paragraphs mushes it with the rest of the content there. Jytdog ( talk) 02:13, 29 August 2016 (UTC)
When we use a term such as "unearned" in Wikipedia's voice, we are making a leap here. Proper policy is to cite sources, not to editorially assert this as simple fact. And using parenthetical comments about any such case is against common sense. Collect ( talk) 13:26, 29 August 2016 (UTC)
There have been two edits recently adding and then reverting the "Known for" line of the infobox with "Raising the prices of EpiPens by 400%". Realizing we must be mindful of WP:BLP, this appears accurate to include, to me. In a quick google news search, both recent [1] [2] and older [3] references refer to this event. Even references to Heather Bresch in articles not primarily about her refer to this fact. [4] [5] [6] [7] I don't think there is a "standard" for being Known for, but I believe there is sufficient reliable sources for it's use here. Hopefully we can find a consensus here.
(This isn't a particularly active article, notifying editors who have worked on the article recently: Edwardx, Shearonink, Nomoskedasticity, Michael Powerhouse, Koavf, Bitmapped, Joeykai) Dbsseven ( talk) 22:20, 5 June 2018 (UTC)
She has three controversial/noteworthy things that she is "known for". Instead of trying to cover them in an infobox, IMHO it would be better to have a Controversy section or similar. Lou Sander ( talk) 22:38, 27 June 2018 (UTC)
Hi. Either Heather Bresch started working for Mylan in 1991 or in 1992 - both stories cannot be correct, as written... This needs to be definitively cleaned up. — Preceding unsigned comment added by Stevenmitchell ( talk • contribs) 05:10, 19 July 2021 (UTC)
Discrepancy. Her resume in the right-hand column of the article states that she received a BA from Harvard Law, whereas the text of the article states that she received a BA from WV University. And, isn’t a law degree is a JD? 72.227.105.116 ( talk) 02:45, 20 December 2021 (UTC)
Summary and personal life sections are in disagreement. 152.44.208.181 ( talk) 21:05, 30 May 2023 (UTC)